Medulloblastoma arises through multiple molecular mechanisms reflecting its umbrella classification. The packet certifies associations with two genes: CTNNB1 (chromosome 3), implicated in WNT signaling pathway biology, and PTCH2 (chromosome 1), implicated in Hedgehog pathway biology. The disorder exhibits heterogeneous inheritance patterns, with certified forms including multifactorial, autosomal recessive, and autosomal dominant, consistent with the broad molecular subgroup diversity of the disease. Some subtypes arise predominantly through somatic alterations; the packet does not certify a specific germline versus somatic distinction for each associated gene.

Medulloblastoma is characterized as a malignant embryonal neoplasm of the cerebellum with cerebrospinal fluid metastatic potential. The disease definition identifies four recognized histologic variants: classic medulloblastoma, large cell/anaplastic medulloblastoma, desmoplastic/nodular medulloblastoma, and medulloblastoma with extensive nodularity. Specific diagnostic methods beyond the disease definition and histologic classification are not certified in this packet.

Certified treatment information is not available in this packet. FDA-approved treatment coverage for medulloblastoma is absent or not certified in this source. Investigational research activity is substantial, as reflected in the certified clinical trial landscape described in the Research section.

Certified prognosis information is not available in this packet beyond the disease classification. Medulloblastoma is classified as a malignant, invasive neoplasm with documented cerebrospinal fluid metastatic potential.

Medulloblastoma has extensive active research activity. The packet certifies 80 active clinical trials. Among the certified trial records: NCT03911388 (Phase 1, Recruiting) is an oncolytic herpesvirus study in children with recurrent or refractory cerebellar brain tumors, sponsored by MD Anderson Cancer Center, with a projected completion of September 2027. NCT04743661 (Phase 2, Active Not Recruiting) examines 131I-Omburtamab in recurrent medulloblastoma and ependymoma, sponsored by the Pediatric Brain Tumor Consortium, projected to complete September 2027. NCT03155620 (Phase 2, Active Not Recruiting) is the Pediatric MATCH Screening Trial for genetically targeted therapy in relapsed or refractory pediatric solid tumors including medulloblastoma, sponsored by NCI, projected to complete January 2027. NCT06161519 (Phase 1, Recruiting) examines PLX038 in primary CNS tumors with MYC or MYCN amplifications, sponsored by NCI, projected to complete November 2033. NCT04337177 (Phase 1, Active Not Recruiting) studies oral irinotecan formulation with temozolomide in recurrent pediatric solid tumors, projected to complete December 2026. Certified intervention approaches across the trial portfolio include drug therapy, biologic therapy, and procedural interventions, with a mixed sponsor profile. The research landscape digest documents 465 classified publications with active gene therapy and biomarker publication activity.